Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry |
| |
Authors: | Helge Möllmann MD Albrecht Elsässer MD Holger Nef MD Steffen Schneider PhD Christoph A. Nienaber MD Gert Richardt MD Michael Weber MD Malte Kelm MD Benny Levenson MD Tassilo Bonzel MD Ulrich Tebbe MD Georg Sabin MD Thomas Pfannebecker Jochen Senges MD Christian W. Hamm MD |
| |
Affiliation: | 1. Kerckhoff Heart Centre, Bad Nauheim, Germany 11. Department of Cardiology, Kerckhoff – Klinik, Benekestr.2-8, 61231, Bad Nauheim, Germany 2. Herzzentrum Ludwigshafen, Ludwigshafen, Germany 3. Universit?tsklinik Rostock, Rostock, Germany 4. Herzzentrum Bad Segeberg, Bad Segeberg, Germany 5. Universit?tsklinik Aachen, Aachen, Germany 6. Kardiologische Praxis Berlin, Berlin, Germany 7. Klinikum Fulda, Fulda, Germany 8. Klinikum Lippe-Detmold, Detmold, Germany 10. Elisabeth Krankenhaus Essen, Essen, Germany 9. Medical Affairs Cordis Germany, Bremerhaven, Germany
|
| |
Abstract: | Aims Drug-eluting stents have been reported to effectively reduce in-stent restenosis (ISR). However, the effectiveness and safety have yet been investigated only in small trials or case series. The aim of this prospective large scale registry was to show that treatment of ISR with sirolimus eluting stents (SES) is safe, effective and feasible in daily routine. Methods and results The German Cypher registry prospectively enrolled 6,555 patients undergoing implantation with SES for various indications, including 1,533 patients treated for ISR. Follow-up data (median 6.6 months) of this cohort was available for 1,531 patients (99.8%). Of these patients 75.8% were male. Of these patients 36.5% (n = 552) presented with acute coronary syndromes. In total, 1,932 SES were used with successful implantation in 98.9%. MI during hospitalization was observed in 0.7% (n = 11) while in-hospital mortality was only 0.1% (n = 2). MACE-rate at follow-up was 13.8% (n = 211) including a mortality of 1.3% (n = 20) and MI in 1.9% (n = 29). Total revascularization procedures including CABG (1.7%) were necessary in 12.3% (n = 186). Target vessel revascularization (TVR) rate was 9.3% (n = 139) and thus similar to patients with de novo lesions (8.1%, P = 0.69). Ten patients (0.65%) suffered from subacute stent thrombosis Vs. 0.24% observed in patients with de novo lesions (P = 0.03). Conclusion This large registry confirms that treatment of ISR with sirolimus-eluting-stents is effective and save with good clinical results at index procedure and follow-up. TVR was not different from de novo lesions. |
| |
Keywords: | sirolimus rapamycin drug eluting stent in-stent restenosis |
本文献已被 SpringerLink 等数据库收录! |
|